CAMBRIDGE, Mass. — Two Chinese drug makers have already taken advantage of new rules that ease the way for pre-revenue biotechs to raise capital on Hong Kong’s stock exchange: hepatology-focused drug developer Ascletis applied to list there last month, and diabetes drug maker Hua Medicine did the same on Wednesday.
But Hong Kong officials want U.S. drug makers to follow in their footsteps — and so a delegation traveled 8,000 miles to make their case during the BIO conference in Boston. In an event on Wednesday billed as a roadshow, officials from the stock exchange and other regional industry boosters talked up the virtues of doing business in Hong Kong to a room full of executives from U.S. drug makers, along with industry investors and bankers.
About the Author Reprints
